Single-cell transcriptomics identifies fibroblast associated immune heterogeneity and prognostic signatures in bladder cancer

Key Points

• Bladder cancer shows distinct immune heterogeneity linked with fibroblast activity, indicating diverse patient responses.
• The findings highlight specific prognostic signatures that may serve as valuable biomarkers for treatment decisions.
• Assessment employs single-cell transcriptomics to examine tumor microenvironments, unraveling complex cellular interactions.
• Therapeutic strategies could be tailored based on the identified signatures, potentially improving patient outcomes.